WorldCare Clinical (WCC), an imaging CRO for clinical trials in the pharmaceutical, biotechnology and medical device industries, has promoted former chief medical officer (CMO) Richard Walovitch to president.
As president, Walovitch will continue to provide medical leadership for the entire organisation.
He will also be responsible for directing the operations, regulatory, sales and marketing activities and play a vital role in defining the strategic vision of the company.
Previously, he served as senior vice president of clinical research at Acusphere, where he was responsible for the development and implementation of worldwide clinical strategies for product opportunities in multiple therapeutic areas, including cardiology imaging, oncology, pulmonology, and analgesia.
WCC managing director Michael O’Brien said that the promotion of Richard to president is a reflection of his many contributions to WorldCare Clinical’s success in expanding the breadth and depth of their service offerings.
“Rick’s years of experience and scientific contributions in the area of medical imaging assessment strategies and processes in clinical research have allowed our company to deliver quality services to our clients in a timely and efficient manner,” O’Brien said.
“Under Rick’s leadership, WCC is setting new standards of performance testing and training in the critical area of reader reliability, as well as delivering quality and efficiency improvement approaches to end point assessment committee processes.”